{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:56:27Z","timestamp":1791921387658,"version":"4.3.4"},"reference-count":116,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000761","name":"Imperial College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000761","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["201808060050"],"award-info":[{"award-number":["201808060050"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000299","name":"Ovarian Cancer Action","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000299","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.celrep.2023.113307","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T12:15:33Z","timestamp":1697717733000},"page":"113307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma"],"prefix":"10.1016","volume":"42","author":[{"given":"Yuewei","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Spear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc P.","family":"Lorentzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gruet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"McKinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiharu","family":"Wickremesinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madelen R.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"McNeish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector C.","family":"Keun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6157-9886","authenticated-orcid":false,"given":"Anke","family":"Nijhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.celrep.2023.113307_bib1","series-title":"Ovarian Cancer Survival Statistics","year":"2022"},{"key":"10.1016\/j.celrep.2023.113307_bib2","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3390\/ijms20040952","article-title":"High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints","volume":"20","author":"Lisio","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.celrep.2023.113307_bib3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.critrevonc.2019.08.002","article-title":"Hopes and failures in front-line ovarian cancer therapy","volume":"143","author":"Tsibulak","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.celrep.2023.113307_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2018.12.002","article-title":"PARP inhibitors in ovarian cancer","volume":"73","author":"Franzese","year":"2019","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.celrep.2023.113307_bib5","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Berchuck","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2023.113307_bib6","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/annonc\/mdw142","article-title":"BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer","volume":"27","author":"Moschetta","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.celrep.2023.113307_bib7","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2023.113307_bib8","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2023.113307_bib9","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.celrep.2023.113307_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103145","article-title":"Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials","volume":"157","author":"Hao","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.celrep.2023.113307_bib11","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41416-018-0271-y","article-title":"Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy","volume":"119","author":"Friedlander","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.celrep.2023.113307_bib12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s12957-020-01931-7","article-title":"The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis","volume":"18","author":"Yang","year":"2020","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.celrep.2023.113307_bib13","article-title":"Comparative Efficacy and Safety of Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Ovarian Cancer: A Systematic Review and Network Meta-Analysis","volume":"12","author":"Luo","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.celrep.2023.113307_bib14","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.tcb.2019.07.008","article-title":"PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells","volume":"29","author":"Noordermeer","year":"2019","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.celrep.2023.113307_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.sbi.2022.102461","article-title":"Structural studies of the spliceosome: Bridging the gaps","volume":"77","author":"Tholen","year":"2022","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.celrep.2023.113307_bib16","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.cell.2017.04.033","article-title":"An Atomic Structure of the Human Spliceosome","volume":"169","author":"Zhang","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2023.113307_bib17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/cr.2018.14","article-title":"Structure of the human activated spliceosome in three conformational states","volume":"28","author":"Zhang","year":"2018","journal-title":"Cell Res."},{"key":"10.1016\/j.celrep.2023.113307_bib18","first-page":"536","article-title":"Dysregulation and therapeutic targeting of RNA splicing in cancer","volume":"3","author":"Stanley","year":"2022","journal-title":"Nat. Can. (Ott.)"},{"key":"10.1016\/j.celrep.2023.113307_bib19","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.trecan.2020.04.011","article-title":"RNA Splicing and Cancer","volume":"6","author":"Wang","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.celrep.2023.113307_bib20","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1093\/carcin\/bgt216","article-title":"Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer","volume":"34","author":"Zhang","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.celrep.2023.113307_bib21","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1158\/0008-5472.CAN-16-0186","article-title":"The BRCA1-\u039411q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin","volume":"76","author":"Wang","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2023.113307_bib22","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1038\/onc.2014.237","article-title":"BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin","volume":"34","author":"Paul","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.celrep.2023.113307_bib23","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41419-021-03581-3","article-title":"Splicing factor USP39 promotes ovarian cancer malignancy through maintaining efficient splicing of oncogenic HMGA2","volume":"12","author":"Wang","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.celrep.2023.113307_bib24","doi-asserted-by":"crossref","DOI":"10.1177\/15330338211067911","article-title":"Alternative Splicing: A New Therapeutic Target for Ovarian Cancer","volume":"21","author":"Yao","year":"2022","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.celrep.2023.113307_bib25","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/s41598-021-03836-1","article-title":"Comprehensive characterization of 11 prognostic alternative splicing events in ovarian cancer interacted with the immune microenvironment","volume":"12","author":"Yue","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.celrep.2023.113307_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-89778-0","article-title":"Alternative splicing acts as an independent prognosticator in ovarian carcinoma","volume":"11","author":"Ouyang","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.celrep.2023.113307_bib27","article-title":"Systematic Profiling of Alternative Splicing Events in Ovarian Cancer","volume":"11","author":"Liu","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.celrep.2023.113307_bib28","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13048-021-00866-1","article-title":"Systematic analysis of the relationship between ovarian cancer prognosis and alternative splicing","volume":"14","author":"Zhang","year":"2021","journal-title":"J.\u00a0Ovarian Res."},{"key":"10.1016\/j.celrep.2023.113307_bib29","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ygyno.2017.11.028","article-title":"Systematic profiling of alternative splicing signature reveals prognostic predictor for ovarian cancer","volume":"148","author":"Zhu","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.celrep.2023.113307_bib30","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/s41588-019-0395-x","article-title":"A transcriptome-wide association study of high-grade serous epithelial ovarian cancer identifies new susceptibility genes and splice variants","volume":"51","author":"Gusev","year":"2019","journal-title":"Nat. Genet."},{"key":"10.1016\/j.celrep.2023.113307_bib31","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1111\/bph.15331","article-title":"RNA-binding motif protein 39 (RBM39): An emerging cancer target","volume":"179","author":"Xu","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.celrep.2023.113307_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/science.aal3755","article-title":"Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15","volume":"356","author":"Han","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.celrep.2023.113307_bib33","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/nchembio.2363","article-title":"Selective degradation of splicing factor CAPERalpha by anticancer sulfonamides","volume":"13","author":"Uehara","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.celrep.2023.113307_bib34","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/S0959-8049(01)00275-1","article-title":"E7070, a novel sulphonamide agent with potent antitumour activity in\u00a0vitro and in\u00a0vivo","volume":"37","author":"Ozawa","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.celrep.2023.113307_bib35","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.01.010","article-title":"Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia","volume":"35","author":"Wang","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.celrep.2023.113307_bib36","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/s41467-022-28907-3","article-title":"Indisulam targets RNA splicing and metabolism to serve as a therapeutic strategy for high-risk neuroblastoma","volume":"13","author":"Nijhuis","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2023.113307_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abj5405","article-title":"Targeting the spliceosome through RBM39 degradation results in exceptional responses in high-risk neuroblastoma models","volume":"7","author":"Singh","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.celrep.2023.113307_bib38","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"key":"10.1016\/j.celrep.2023.113307_bib39","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.celrep.2023.113307_bib40","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.cell.2013.08.003","article-title":"An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules","volume":"154","author":"Basu","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2023.113307_bib41","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nchembio.1986","article-title":"Correlating chemical sensitivity and basal gene expression reveals mechanism of action","volume":"12","author":"Rees","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.celrep.2023.113307_bib42","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1158\/2159-8290.CD-15-0235","article-title":"Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity DatasetHarnessing Connectivity in a Sensitivity Dataset","volume":"5","author":"Seashore-Ludlow","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.celrep.2023.113307_bib43","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1016\/j.cell.2021.05.038","article-title":"Pharmacologic modulation of RNA splicing enhances anti-tumor immunity","volume":"184","author":"Lu","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2023.113307_bib44","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.bbrc.2016.03.108","article-title":"Functional interaction between nonreceptor tyrosine kinase c-Abl and SR-Rich protein RBM39","volume":"473","author":"Mai","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.celrep.2023.113307_bib45","doi-asserted-by":"crossref","first-page":"E5593","DOI":"10.1073\/pnas.1419161111","article-title":"rMATS: robust and flexible detection of differential alternative splicing from replicate RNA-Seq data","volume":"111","author":"Shen","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2023.113307_bib46","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-15-0945","article-title":"ATM Mutations in Cancer: Therapeutic Implications","volume":"15","author":"Choi","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.celrep.2023.113307_bib47","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1086\/301673","article-title":"Ataxia-telangiectasia: identification and detection of founder-effect mutations in the ATM gene in ethnic populations","volume":"62","author":"Telatar","year":"1998","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.celrep.2023.113307_bib48","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrm4063","article-title":"Nonsense-mediated mRNA decay: an intricate machinery that shapes transcriptomes","volume":"16","author":"Lykke-Andersen","year":"2015","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.celrep.2023.113307_bib49","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/ncomms3126","article-title":"Evaluating cell lines as tumour models by comparison of genomic profiles","volume":"4","author":"Domcke","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2023.113307_bib50","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: Synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.celrep.2023.113307_bib51","series-title":"CompuSyn for Drug Combinations: A Computer Program for Quantitation of Synergism and Antagonism in Drug Combinations, and the Determination of IC50 and ED50 Values","author":"Chou","year":"2005"},{"key":"10.1016\/j.celrep.2023.113307_bib52","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","article-title":"Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib","volume":"13","author":"Murai","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.celrep.2023.113307_bib53","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2023.113307_bib54","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1158\/1541-7786.MCR-15-0191-T","article-title":"Mechanistic Dissection of PARP1 Trapping and the Impact on In\u00a0Vivo Tolerability and Efficacy of PARP Inhibitors","volume":"13","author":"Hopkins","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.celrep.2023.113307_bib55","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1158\/1541-7786.MCR-18-0138","article-title":"PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow","volume":"17","author":"Hopkins","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.celrep.2023.113307_bib56","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.annonc.2020.10.470","article-title":"A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance","volume":"32","author":"Tobalina","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.celrep.2023.113307_bib57","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","article-title":"BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma","volume":"9","author":"Lin","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.celrep.2023.113307_bib58","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1016\/j.molcel.2021.06.011","article-title":"Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency","volume":"81","author":"Cong","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.celrep.2023.113307_bib59","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1038\/s41388-020-1328-y","article-title":"Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells","volume":"39","author":"Lloyd","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.celrep.2023.113307_bib60","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.tranon.2017.01.007","article-title":"ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib","volume":"10","author":"Wang","year":"2017","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.celrep.2023.113307_bib61","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41416-019-0565-8","article-title":"Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated\/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells","volume":"121","author":"Jette","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.celrep.2023.113307_bib62","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1042\/BST20191092","article-title":"Systems approach to rational combination therapy: PARP inhibitors","volume":"48","author":"Sun","year":"2020","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.celrep.2023.113307_bib63","first-page":"5934","article-title":"Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation","volume":"60","author":"Ahn","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2023.113307_bib64","doi-asserted-by":"crossref","first-page":"42462","DOI":"10.1074\/jbc.C100466200","article-title":"ATM phosphorylates histone H2AX in response to DNA double-strand breaks","volume":"276","author":"Burma","year":"2001","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.celrep.2023.113307_bib65","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1158\/0008-5472.CAN-03-3207","article-title":"ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation","volume":"64","author":"Stiff","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2023.113307_bib66","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/j.1751-1097.2011.00995.x","article-title":"\u03b3H2Ax: Biomarker of Damage or Functional Participant in DNA Repair \u201cAll that Glitters Is not Gold","volume":"87","author":"Cleaver","year":"2011","journal-title":"Photochem. Photobiol."},{"key":"10.1016\/j.celrep.2023.113307_bib67","doi-asserted-by":"crossref","first-page":"6870","DOI":"10.1073\/pnas.1002175107","article-title":"A minority of foci or pan-nuclear apoptotic staining of gammaH2AX in the S phase after UV damage contain DNA double-strand breaks","volume":"107","author":"de Feraudy","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2023.113307_bib68","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/sj.onc.1209863","article-title":"ATR-dependent radiation-induced gamma H2AX foci in bystander primary human astrocytes and glioma cells","volume":"26","author":"Burdak-Rothkamm","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.celrep.2023.113307_bib69","doi-asserted-by":"crossref","first-page":"47759","DOI":"10.1074\/jbc.C100569200","article-title":"Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress","volume":"276","author":"Ward","year":"2001","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.celrep.2023.113307_bib70","doi-asserted-by":"crossref","first-page":"9677","DOI":"10.1074\/jbc.C300554200","article-title":"UV-induced ataxia-telangiectasia-mutated and Rad3-related (ATR) activation requires replication stress","volume":"279","author":"Ward","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.celrep.2023.113307_bib71","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1083\/jcb.201007074","article-title":"Chk1 inhibits replication factory activation but allows dormant origin firing in existing factories","volume":"191","author":"Ge","year":"2010","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.celrep.2023.113307_bib72","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1128\/MCB.26.8.3319-3326.2006","article-title":"Chk1 requirement for high global rates of replication fork progression during normal vertebrate S phase","volume":"26","author":"Petermann","year":"2006","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.celrep.2023.113307_bib73","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/B978-0-12-380888-2.00003-0","article-title":"The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer","volume":"108","author":"Smith","year":"2010","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.celrep.2023.113307_bib74","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.molcel.2017.05.001","article-title":"Replication Catastrophe: When a Checkpoint Fails because of Exhaustion","volume":"66","author":"Toledo","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.celrep.2023.113307_bib75","doi-asserted-by":"crossref","first-page":"21767","DOI":"10.1074\/jbc.M300229200","article-title":"Chk1 Mediates S and G2 Arrests through Cdc25A Degradation in Response to DNA-damaging Agents","volume":"278","author":"Xiao","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.celrep.2023.113307_bib76","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.molcel.2014.12.003","article-title":"Interaction of Chk1 with Treslin negatively regulates the initiation of chromosomal DNA replication","volume":"57","author":"Guo","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.celrep.2023.113307_bib77","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/s41467-017-01401-x","article-title":"ATR kinase inhibition induces unscheduled origin firing through a Cdc7-dependent association between GINS and And-1","volume":"8","author":"Moiseeva","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2023.113307_bib78","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1158\/0008-5472.CAN-16-1272","article-title":"CRISPR\/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma","volume":"76","author":"Walton","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2023.113307_bib79","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17119-1","article-title":"CRISPR\/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity","volume":"7","author":"Walton","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.celrep.2023.113307_bib80","first-page":"284","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.celrep.2023.113307_bib81","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.soncn.2019.02.001","article-title":"Ovarian Cancer: An Integrated Review","volume":"35","author":"Stewart","year":"2019","journal-title":"Semin. Oncol. Nurs."},{"key":"10.1016\/j.celrep.2023.113307_bib82","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1470-2045(21)00303-X","article-title":"Immunotherapy in ovarian cancer: we are not there yet","volume":"22","author":"Barber","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.celrep.2023.113307_bib83","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/bcp.15015","article-title":"Identification of different side effects between PARP inhibitors and their polypharmacological multi-target rationale","volume":"88","author":"Sandhu","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.celrep.2023.113307_bib84","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.bmcl.2003.09.062","article-title":"Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX","volume":"14","author":"Abbate","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.celrep.2023.113307_bib85","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1080\/13543784.2018.1548608","article-title":"Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors","volume":"27","author":"Supuran","year":"2018","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.celrep.2023.113307_bib86","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3390\/metabo10010039","article-title":"Sulfonamide Inhibition Profile of the \u03b2-Carbonic Anhydrase from Malassezia restricta, An Opportunistic Pathogen Triggering Scalp Conditions","volume":"10","author":"Del Prete","year":"2020","journal-title":"Metabolites"},{"key":"10.1016\/j.celrep.2023.113307_bib87","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/s41467-020-14620-6","article-title":"Genetic screens in isogenic mammalian cell lines without single cell cloning","volume":"11","author":"DeWeirdt","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2023.113307_bib88","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41467-023-35880-y","article-title":"CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer","volume":"14","author":"Tsujino","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2023.113307_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2020.102803","article-title":"CRISPR\/CAS9-based DNA damage response screens reveal gene-drug interactions","volume":"87","author":"Su","year":"2020","journal-title":"DNA Repair"},{"key":"10.1016\/j.celrep.2023.113307_bib90","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41586-018-0340-7","article-title":"The shieldin complex mediates 53BP1-dependent DNA repair","volume":"560","author":"Noordermeer","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2023.113307_bib91","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41586-018-0291-z","article-title":"CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions","volume":"559","author":"Zimmermann","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2023.113307_bib92","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1186\/s12885-016-2754-7","article-title":"53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells","volume":"16","author":"Hong","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.celrep.2023.113307_bib93","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1158\/1535-7163.MCT-18-1394","article-title":"Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically","volume":"19","author":"Riches","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.celrep.2023.113307_bib94","doi-asserted-by":"crossref","first-page":"111026","DOI":"10.18632\/oncotarget.22195","article-title":"Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in\u00a0vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer","volume":"8","author":"Brill","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.celrep.2023.113307_bib95","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040878","article-title":"Exploring the Synergy between PARP and CHK1 Inhibition in Matched BRCA2 Mutant and Corrected Cells","volume":"12","author":"Smith","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.celrep.2023.113307_bib96","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1158\/0008-5472.CAN-10-1252","article-title":"CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors","volume":"71","author":"Anderson","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2023.113307_bib97","doi-asserted-by":"crossref","DOI":"10.1038\/celldisc.2015.46","article-title":"Involvement of PARP1 in the regulation of alternative splicing","volume":"2","author":"Matveeva","year":"2016","journal-title":"Cell Discov."},{"key":"10.1016\/j.celrep.2023.113307_bib98","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13072-019-0261-1","article-title":"Coupling of PARP1-mediated chromatin structural changes to transcriptional RNA polymerase II elongation and cotranscriptional splicing","volume":"12","author":"Matveeva","year":"2019","journal-title":"Epigenet. Chromatin"},{"key":"10.1016\/j.celrep.2023.113307_bib99","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1038\/s41598-019-39969-7","article-title":"PARP1 is a versatile factor in the regulation of mRNA stability and decay","volume":"9","author":"Matveeva","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.celrep.2023.113307_bib100","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/1873-3468.14065","article-title":"PARP1\u2013RNA interaction analysis: PARP1 regulates the expression of extracellular matrix-related genes in HK-2 renal proximal tubular epithelial cells","volume":"595","author":"Ke","year":"2021","journal-title":"FEBS Lett."},{"key":"10.1016\/j.celrep.2023.113307_bib101","doi-asserted-by":"crossref","first-page":"17325","DOI":"10.1074\/jbc.M114.558825","article-title":"Cancer-relevant splicing factor CAPERalpha engages the essential splicing factor SF3b155 in a specific ternary complex","volume":"289","author":"Loerch","year":"2014","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.celrep.2023.113307_bib102","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1021\/jm9902638","article-title":"Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle","volume":"42","author":"Owa","year":"1999","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.celrep.2023.113307_bib103","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.celrep.2019.09.079","article-title":"Aryl Sulfonamides Degrade RBM39 and RBM23 by Recruitment to CRL4-DCAF15","volume":"29","author":"Ting","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.celrep.2023.113307_bib104","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/s41375-020-0729-9","article-title":"Biomarkers for RBM39 degradation in acute myeloid leukemia","volume":"34","author":"Hsiehchen","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.celrep.2023.113307_bib105","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/path.2091","article-title":"A candidate precursor to serous carcinoma that originates in the distal fallopian tube","volume":"211","author":"Lee","year":"2007","journal-title":"J.\u00a0Pathol."},{"key":"10.1016\/j.celrep.2023.113307_bib106","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/IGC.0b013e318199009c","article-title":"The fallopian tube: primary site of most pelvic high-grade serous carcinomas","volume":"19","author":"Salvador","year":"2009","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.celrep.2023.113307_bib107","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.celrep.2019.12.034","article-title":"Mouse Ovarian Cancer Models Recapitulate the Human Tumor Microenvironment and Patient Response to Treatment","volume":"30","author":"Maniati","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.celrep.2023.113307_bib108","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/s13046-021-02124-0","article-title":"Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models","volume":"40","author":"Coulson-Gilmer","year":"2021","journal-title":"J.\u00a0Exp. Clin. Cancer Res."},{"key":"10.1016\/j.celrep.2023.113307_bib109","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.celrep.2023.113307_bib110","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.celrep.2023.113307_bib111","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.bbagrm.2016.06.007","article-title":"Global regulation of alternative RNA splicing by the SR-rich protein RBM39","volume":"1859","author":"Mai","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.celrep.2023.113307_bib112","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nprot.2008.211","article-title":"Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources","volume":"4","author":"Huang","year":"2009","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.celrep.2023.113307_bib113","doi-asserted-by":"crossref","first-page":"W216","DOI":"10.1093\/nar\/gkac194","article-title":"DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update)","volume":"50","author":"Sherman","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.celrep.2023.113307_bib114","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative C(T) method","volume":"3","author":"Schmittgen","year":"2008","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.celrep.2023.113307_bib115","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2023.113307_bib116","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."}],"container-title":["Cell Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124723013190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124723013190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T11:59:39Z","timestamp":1761911979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211124723013190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":116,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S2211124723013190"],"URL":"https:\/\/doi.org\/10.1016\/j.celrep.2023.113307","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.01.18.524417","asserted-by":"object"}]},"ISSN":["2211-1247"],"issn-type":[{"value":"2211-1247","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma","name":"articletitle","label":"Article Title"},{"value":"Cell Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.celrep.2023.113307","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"113307"}}